Source published 29 October 2026 by MHRA Safety Alerts MHRA Issues Class 2 Recall for Batch of Accord Lercanidipine 10mg Tablets The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 medicines recall concerning a specific batch of lercanidipine hydrochloride 10mg film-coated tablets distributed by Accord-UK Ltd. According to the regulatory notification […]
Read More
Key Takeaways Unprecedented September Demand: Urgent and emergency services saw record activity for the month, recording 2.44 million emergency department attendances and 806,707 ambulance incidents. Capacity Constraints: Adult acute bed occupancy reached an average of 94.9% in September, exacerbated by an average of 13,647 medically fit adult inpatients delayed from discharge daily. Elective Care Trends: […]
Read More
Source published 18 October 2026 by Department of Health and Social Care (GOV.UK) Key takeaways The Department of Health and Social Care has allocated nearly £140 million across 14 urgent care schemes in England to improve winter resilience. Funding will support major emergency department refurbishments, new Urgent Treatment Centres (UTCs), Same Day Emergency Care (SDEC) […]
Read More
Source published 19 October 2026 by MHRA news (GOV.UK) Key Takeaways The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised plozasiran (Redemplo) as an adjunct to a low-fat diet for adults with familial chylomicronaemia syndrome (FCS). Plozasiran acts by inhibiting hepatic production of apolipoprotein C3, thereby lowering circulating triglyceride levels. The therapy is delivered […]
Read More